Li J, et al. - Researchers analyzed randomized controlled trials (RCTs) reporting the skin toxicities of anti-EGFR monoclonal antibody (EGFR-MoAbs) in cancer patients. They performed a systematic evaluation of the relevant studies identified from EMBASE, MEDLINE, and PubMed until November 2017. The meta-analysis included a total of 65 RCTs and 25,994 patients. They found a significantly increased risk of developing skin toxicity, all-grade and high-grade skin toxicity, such as rash, hand–foot syndrome, dry skin and oral mucositis, in association with the use of EGFR-MoAbs. The most commonly documented skin toxicity was rash. Awareness by physicians regarding skin toxicity is important and they should monitor cancer patients on EGFR-MoAbs.